Allergy Therapeutics plc (LON:AGY – Get Free Report) traded down 17.5% during trading on Monday . The company traded as low as GBX 4 ($0.05) and last traded at GBX 4 ($0.05). 3,016 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 761,260 shares. The stock had previously closed at GBX 4.85 ($0.06).
Allergy Therapeutics Trading Down 2.5 %
The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The stock’s fifty day moving average price is GBX 4.56 and its 200 day moving average price is GBX 4.20. The stock has a market capitalization of £209.36 million, a P/E ratio of -75.00, a PEG ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics Company Profile
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- How to Start Investing in Real Estate
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- How to Evaluate a Stock Before Buying
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
